---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-025240"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:05:33.481277+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott completes $20B senior notes offering to fund Exact Sciences acquisition

## Summary
- Issued $20B in eight tranches: Floating Rate Notes due 2029, fixed-rate notes from 3.700% to 5.600% with maturities 2029–2066.
- Net proceeds to fund Exact Sciences acquisition (announced Nov 2025), repay Exact Sciences debt, pay fees, and general purposes.
- If Exact Sciences acquisition not consummated by Feb 17, 2027, Abbott must redeem notes at 101% plus accrued interest.
- Underwriters include Morgan Stanley, Barclays, BofA Securities, J.P. Morgan.

## SEC filing metadata
- accession: 0001104659-26-025240
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/0001104659-26-025240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/tm264905d8_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-025240
- JSON: https://secwatch.observer/filing/0001104659-26-025240.json
- Plain text: https://secwatch.observer/filing/0001104659-26-025240.txt

## Key facts
- Debt Financings
  ABBOTT LABORATORIES incurred senior notes of $20,000,000,000 aggregate principal amount with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC at Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30 maturing 2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066.
  - Instrument: senior notes
  - Principal: $20,000,000,000 aggregate principal amount
  - Counterparty: Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC
  - Rate: Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30
  - Maturity: 2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066
  - Event: incurrence
  source text: On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/0001104659-26-025240-index.htm
- Material Agreements
  ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC
  - Value: $20,000,000,000 aggregate principal amount
  - Effective: 2026-02-23
  source text: The Notes were sold pursuant to a pricing agreement, dated February 23, 2026 (the “Pricing Agreement”), by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/0001104659-26-025240-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.